Chabiotech Co.,Ltd.

$ 11 930.00 -1.24 %

Chabiotech Co.,Ltd. is a global biotechnology firm specializing in the development of cell and gene therapies, particularly those involving stem and immune cells, with operations in South Korea and internationally. The company's comprehensive offerings include umbilical cord blood storage for treating intractable conditions, alongside various regenerative medicine solutions. It also manages storage services for immune and stem cells, provides anti-aging treatments, and delivers therapeutic solutions for debilitating illnesses. Furthermore, Chabiotech runs medical wellness initiatives encompassing fitness, spa services, and nutritional supplements. Leveraging its extensive research and development as well as clinical expertise, the company provides customized services covering product development, manufacturing, clinical trials, and commercialization. Chabiotech assists clients with optimizing IT system infrastructure and operations, and offers consulting services for the establishment, management, and growth of its proprietary Chaum model. Additionally, the company provides solutions for maternal-focused genomic testing and personalized healthcare. It is actively engaged in developing advanced immune cell therapies, such as CBT101 for recurrent glioblastoma and solid cancers, and both CBT111 and CAR-NK treatments specifically targeting solid tumors. Its stem cell pipeline features CordSTEM-DD for chronic back pain, CordSTEM-POI for premature ovarian failure, CordSTEM-ST for stroke, CBT-NPC for Parkinson's disease, and hESC-RPE for addressing macular degeneration and Stargardt's disease. Beyond its core bio-pharmaceutical activities, Chabiotech also offers IVF (fertility) services, manufactures cosmetics and their raw materials, supplies medical devices, provides bioinsurance storage, and conducts various research services. Established in 2002, the company maintains its headquarters in Seoul, South Korea.

CEO: Gyu-Beom Han - https://www.chabio.com

Price objectif

-

Recommandation

-

DCF

$ -115 989.16

Loading data...

085660.KQ vs S&P500

Loading data...

No data available.

Quick ratio

0.83

indicates that the company may have difficulty covering its short-term debts with its readily available assets.

P/E ratio

0.00

may indicate that the company is undervalued or has poor growth prospects.

EPS

0.00

is the net profit of a company divided by the number of outstanding shares, indicating the profit earned per share.

ROE

-19.24 %

indicates low profitability, suggesting that the company is not using equity efficiently to generate profits.

ROIC

-3.07 %

does not generate enough return to cover its financing costs, which indicates value destruction and may pose long-term profitability issues.

WACC

5.61

is a company's average cost of capital, weighted by the proportion of debt and equity in its financing. It represents the minimum return the company must generate to satisfy its investors.

Debt-to-Equity Ratio

1.64

means it relies more on debt, which can increase financial risk.

Free cash flow per share

-3 250.63

is a measure of a company's financial flexibility that is determined by dividing free cash flow by the total number of shares outstanding.

Dividend payout ratio

-1.14 %

indicates that the company is retaining a large portion of its profits to reinvest in growth

Earnings per share

Loading data...

No data available.

Financials

Piotroski score
1 indicates worrying financial health
Altman score
0.68 indicates a high risk of bankruptcy
Loading data...

No data available.

Cash / Debt

Cash Ratio
0.30 indicates liquidity risk, as the company may not have enough cash to meet its immediate obligations
Debt Ratio
0.30 indicates that the company uses little debt to finance its assets, suggesting good financial stability
Loading data...

No data available.

Free Cash Flow

Loading data...

No data available.

Earnings Per Share (annual)

Loading data...

No data available.

Sales

Loading data...

No data available.